ArticleJournal of thoracic disease2025
Diagnostic performance of Xpert MTB/RIF in lymph node tuberculosis in a general hospital.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In general hospitals, tuberculosis (TB) is an important infectious cause of lymphadenopathy, but its etiological diagnosis rate is very low. This study aimed to determine the performance of Xpert MTB/RIF(Xpert) in differentiate tuberculous lymphadenopathy from other causes. Methods: A retrospective pairing study was carried out from August 2015 to July 2024. A total of 229 participants were involved. Microbiological reference standard (MRS) and composite reference standard (CRS) were used as two standards. All patients underwent biopsy measurement and specimens were examined using histopathology, acid-fast bacilli (AFB), liquid culture with/without Xpert. The baseline information, diagnostic methods and time were compared between two groups. The diagnostic values including sensitivity, specificity, accuracy (ACC), Kappa value and area under the curve (AUC) were compared. Results: This study included a total of 229 participants, of whom 150 were in the no Xpert group and 79 in the Xpert group. The median age was 44 [31-58] years, with female proportion of 60.0%. The most common sites of lymphadenopathy are the neck (66%), mediastinum (17%), and abdomen (7%). In patients with lymph node tuberculosis (LNTB), MRS was achieved in 35.4% of cases, while 60.0% fulfilled CRS criteria. No significant differences were observed in MRS percentage or pathology positivity rates between the two groups. The median time from biopsy to diagnosis was significantly shorter in the Xpert group compared to the no Xpert group {2 days [interquartile range (IQR), 1-9 days] Conclusions: Xpert can accelerate the microbiological diagnosis time and reduce the misdiagnose of lymph node granulomatous lesions. The application of Xpert combined with culture or pathology may be the best pattern for the diagnosis of LNTB in general hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.